Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20805225 | 0.73 | DDB1 (0.59) | DDB1CRBNNPY5R | |
| SCHEMBL24783277 | 0.73 | CYP1A2 (0.40) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL24783460 | 0.69 | CRBN (0.60) | DDB1CRBNTSHRHTR2BADAMTS5 | |
| SCHEMBL13839238 | 0.69 | ALDH1A1 (0.47) | NPY5RPKMALDH1A1NPSR1HTR2B | |
| SCHEMBL19061812 | 0.68 | PKM (0.52) | NPY5RPKMALDH1A1TSHRNPSR1 | |
| SCHEMBL24783320 | 0.68 | CRBN (0.54) | DDB1CRBNALDH1A1TSHRKMT2A | |
| SCHEMBL10644848 | 0.68 | NPY5R (0.45) | DDB1CRBNNPY5RPKML3MBTL1 | |
| SCHEMBL20677809 | 0.67 | ALDH1A1 (0.52) | NPY5RPKMALDH1A1TSHRNPSR1 | |
| SCHEMBL2276872 | 0.67 | ALDH1A1 (0.59) | NPY5RPKMALDH1A1TSHRNPSR1 | |
| SCHEMBL10918564 | 0.66 | NPC1 (0.47) | PKMALDH1A1NPSR1PLAUR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885NPY5R 3242/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885NPY5R 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.